AtonRa Partners Sells 566 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

AtonRa Partners lessened its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 8.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 5,772 shares of the biopharmaceutical company’s stock after selling 566 shares during the quarter. AtonRa Partners’ holdings in Intra-Cellular Therapies were worth $413,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Xponance Inc. lifted its stake in shares of Intra-Cellular Therapies by 3.0% during the 4th quarter. Xponance Inc. now owns 5,676 shares of the biopharmaceutical company’s stock worth $407,000 after acquiring an additional 163 shares during the last quarter. Regal Investment Advisors LLC boosted its stake in shares of Intra-Cellular Therapies by 1.4% during the third quarter. Regal Investment Advisors LLC now owns 13,610 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 186 shares during the period. State Board of Administration of Florida Retirement System grew its holdings in shares of Intra-Cellular Therapies by 0.8% in the third quarter. State Board of Administration of Florida Retirement System now owns 26,796 shares of the biopharmaceutical company’s stock worth $1,396,000 after purchasing an additional 200 shares during the last quarter. Bailard Inc. increased its stake in Intra-Cellular Therapies by 1.2% in the 4th quarter. Bailard Inc. now owns 17,080 shares of the biopharmaceutical company’s stock worth $1,223,000 after buying an additional 200 shares during the period. Finally, Signaturefd LLC lifted its holdings in Intra-Cellular Therapies by 85.7% during the 4th quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 239 shares in the last quarter. Institutional investors own 92.33% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Sharon Mates sold 20,565 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the completion of the sale, the chief executive officer now owns 1,050,309 shares in the company, valued at approximately $68,490,649.89. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Intra-Cellular Therapies news, CEO Sharon Mates sold 20,565 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $65.21, for a total value of $1,341,043.65. Following the completion of the sale, the chief executive officer now owns 1,050,309 shares of the company’s stock, valued at $68,490,649.89. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Lawrence J. Hineline sold 13,337 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $69.43, for a total transaction of $925,987.91. The disclosure for this sale can be found here. Over the last three months, insiders have sold 168,487 shares of company stock valued at $11,364,950. 3.40% of the stock is currently owned by insiders.

Intra-Cellular Therapies Stock Performance

ITCI traded down $0.96 on Monday, hitting $72.30. The company had a trading volume of 552,276 shares, compared to its average volume of 934,089. The stock has a market capitalization of $7.00 billion, a price-to-earnings ratio of -49.52 and a beta of 1.02. The stock has a fifty day moving average price of $69.33 and a 200-day moving average price of $64.93. Intra-Cellular Therapies, Inc. has a 12-month low of $45.50 and a 12-month high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14. The firm had revenue of $132.10 million for the quarter, compared to the consensus estimate of $135.97 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. During the same quarter in the previous year, the firm earned ($0.45) EPS. The company’s quarterly revenue was up 50.3% compared to the same quarter last year. Analysts forecast that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ITCI has been the topic of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $86.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 3rd. Robert W. Baird increased their price objective on Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. The Goldman Sachs Group lifted their target price on Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a research report on Wednesday, April 17th. Bank of America increased their price target on Intra-Cellular Therapies from $82.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Finally, TD Cowen lifted their price objective on Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Intra-Cellular Therapies has an average rating of “Moderate Buy” and an average price target of $90.17.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.